



**Medivation Contacts:**

Patrick Machado  
Chief Business & Financial Officer  
(415) 829-4101

Anne Bowdidge  
Senior Director, Investor Relations  
(650) 218-6900

**Astellas Contacts:**

Jenny Kite  
Corporate Communications  
(847) 682-4530

Mike Beyer  
Sam Brown, Inc (media for both companies)  
(773) 463-4211

---

## **Medivation and Astellas Provide Update on PREVAIL Enrollment**

**San Francisco, CA and Tokyo** – June 6, 2012 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced the completion of targeted enrollment of 1,680 patients in the PREVAIL study, a global Phase 3 clinical trial evaluating enzalutamide in men with advanced prostate cancer who have not yet received chemotherapy. The Companies have elected to keep selected sites open in Asia to gain additional information in these unique populations. Medivation is conducting this study under its agreement with Astellas.

"Completing the targeted patient enrollment in PREVAIL is an important step forward in our strategy to evaluate enzalutamide in earlier prostate cancer disease states," said Lynn Seely, M.D., chief medical officer of Medivation. "This study is powered to demonstrate a potential benefit in overall survival in the chemotherapy-naïve patient population."

The randomized, double-blind, placebo-controlled, multi-national Phase 3 PREVAIL trial has enrolled 1,680 patients at sites in the United States, Canada, Europe, Australia, Asia and Israel. The trial enrolled patients with metastatic prostate cancer who progressed despite treatment with androgen deprivation therapy. The co-primary endpoints of the trial are overall survival and progression-free survival; secondary endpoints include time to first skeletal-related event and time to initiation of chemotherapy. The trial is designed to evaluate enzalutamide at a dose of 160 mg taken orally once daily plus standard of care versus placebo plus standard of care.

### **About Enzalutamide (formerly MDV3100)**

Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor. Enzalutamide inhibits androgen receptor signaling in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors.

In the Phase 3 AFFIRM trial of enzalutamide in post-chemotherapy prostate cancer patients common side effects observed more frequently in enzalutamide as compared with placebo-treated patients included fatigue, diarrhea and hot flush. In the AFFIRM trial, seizure was reported in less than 1% of enzalutamide-treated patients. Serious adverse events, adverse events causing patients to stop treatment, and adverse events causing death all were lower in the enzalutamide group than in the placebo group.

**About Medivation**

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug enzalutamide in Phase 3 development to treat advanced prostate cancer and in Phase 1 development to treat breast cancer. For more information, please visit us at [www.medivation.com](http://www.medivation.com).

**About Astellas Pharma Inc.**

Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in Oncology, and has several oncology compounds in development in addition to enzalutamide. For more information on Astellas Pharma Inc., please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

This press release contains forward-looking statements, including statements regarding the continued clinical development of enzalutamide and potential future progress related thereto, the therapeutic potential of enzalutamide, the potential enrollment of additional patients in the PREVAIL study in certain Asian countries, our strategy, and the continued effectiveness of, and continuing collaborative activities and benefits under, Medivation's collaboration agreement with Astellas, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to the timing and potential regulatory approval and commercialization of enzalutamide, the progress, timing and results of Medivation's clinical trials, including the risk that adverse clinical trial results could alone or together with other factors result in the delay or discontinuation of some or all of Medivation's product development activities, the risk that positive results seen in our clinical trials may not be predictive of the results of our ongoing or planned clinical trials and the risk that life-prolonging treatments could prevent ongoing or planned enzalutamide trials from succeeding or could reduce any potential survival benefit that may be shown in these trials even if they do succeed, difficulties or delays in enrolling and retaining patients in Medivation's clinical trials, including as a result of the availability of competing treatments or clinical trials of competing drugs for the same indication, Medivation's dependence on the efforts of and funding by Astellas for the development of enzalutamide, the achievement of development, regulatory and commercial milestones under Medivation's collaboration agreement with Astellas, the manufacturing of Medivation's product candidates, the industry and competitive market, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, Medivation's outstanding convertible senior notes, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended March 31, 2012, filed with the SEC on May 9, 2012. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.